- Home
- KZR vs MIRA Comparison
KZR vs MIRA Comparison
Compare KZR & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZR
- MIRA
- Stock Information
- Founded
- KZR 2015
- MIRA 2020
- Country
- KZR United States
- MIRA United States
- Employees
- KZR N/A
- MIRA N/A
- Industry
- KZR Biotechnology: Pharmaceutical Preparations
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- KZR Health Care
- MIRA Health Care
- Exchange
- KZR Nasdaq
- MIRA Nasdaq
- Market Cap
- KZR 29.7M
- MIRA 25.2M
- IPO Year
- KZR 2018
- MIRA 2023
- Fundamental
- Price
- KZR $3.88
- MIRA $1.30
- Analyst Decision
- KZR Hold
- MIRA
- Analyst Count
- KZR 2
- MIRA 0
- Target Price
- KZR $9.00
- MIRA N/A
- AVG Volume (30 Days)
- KZR 36.2K
- MIRA 900.0K
- Earning Date
- KZR 11-11-2025
- MIRA 11-11-2025
- Dividend Yield
- KZR N/A
- MIRA N/A
- EPS Growth
- KZR N/A
- MIRA N/A
- EPS
- KZR N/A
- MIRA N/A
- Revenue
- KZR N/A
- MIRA N/A
- Revenue This Year
- KZR N/A
- MIRA N/A
- Revenue Next Year
- KZR N/A
- MIRA N/A
- P/E Ratio
- KZR N/A
- MIRA N/A
- Revenue Growth
- KZR N/A
- MIRA N/A
- 52 Week Low
- KZR $3.56
- MIRA $0.73
- 52 Week High
- KZR $9.18
- MIRA $2.56
- Technical
- Relative Strength Index (RSI)
- KZR 49.42
- MIRA 44.19
- Support Level
- KZR $3.79
- MIRA $1.30
- Resistance Level
- KZR $4.10
- MIRA $1.36
- Average True Range (ATR)
- KZR 0.22
- MIRA 0.06
- MACD
- KZR 0.02
- MIRA 0.00
- Stochastic Oscillator
- KZR 61.44
- MIRA 42.86
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.